Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yazan Alsayed

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
British Journal of Haematology|May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsJohn D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2010
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2Yiming Zhou, Lijuan Chen, Bart Barlogie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profilingJeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, et al.
Blood|May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Blood|September 27, 2007
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989Bart Barlogie, Guido Tricot, Jeff Haessler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Blood|August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myelomaLanie K Francis, Yazan Alsayed, Xavier Leleu, et al.
Blood|February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemiaAnne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|May 11, 2007
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular geneticsJohn D Shaughnessy, Jeffrey Haessler, Frits van Rhee, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2010
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2Yiming Zhou, Lijuan Chen, Bart Barlogie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profilingJeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, et al.
Blood|May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Blood|September 27, 2007
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989Bart Barlogie, Guido Tricot, Jeff Haessler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2012
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1Christoph J Heuck, Jackie Szymonifka, Emily Hansen, et al.
Blood|August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic diseaseBart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Blood|June 2, 2011
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3John D Shaughnessy, Pingping Qu, Saad Usmani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myelomaLanie K Francis, Yazan Alsayed, Xavier Leleu, et al.
Blood|February 8, 2007
Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemiaAnne-Sophie Moreau, Xiaoying Jia, Hai T Ngo, et al.
Pageof 3